Information Provided By:
Fly News Breaks for December 20, 2018
IMMU
Dec 20, 2018 | 10:07 EDT
Guggenheim analyst Michael Schmidt said Immunomedics management indicated that a competitor research report published this morning highlighted the company's receipt of an FDA Form-483 citing manufacturing issues regarding sacituzumab. He added that management pointed out to that this Form-483 was already received in August, four months ago, and the company believes it has addressed the manufacturing issues cited. He thinks today's weakness is overdone and keeps a Buy rating on Immunomedics shares.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.